Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2012, Pages

  Radner, Helga ^a   Ramiro, Sofia ^b,c   Buchbinder, Rachelle ^d   Landewé, Robert BM ^c,e   van der Heijde, Désirée ^f   Aletaha, Daniel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL GARCIA DE ORTA   (Portugal)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MONASH UNIVERSITY   (Australia)

^e Sittard Geleen Heerlen   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ARTHRITIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIVER DISEASE; MALE; METHODOLOGY; MIDDLE AGED; PAIN; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NAPROXEN; PAIN; PAIN MANAGEMENT;

EID: 84862646887     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008951.pub2     Document Type: Review

References (125)

1. Roth SH, Boost G. An open trial of naproxen in rheumatoid arthritis patients with significant esophageal, gastric, and duodenal lesions. Journal of Clinical Pharmacology 1975;15:378-84.
2. Adam W. Experiences with 800 mg ibuprofen retard in ambulatory patients with activated osteoarthrosis and extra-articular rheumatic manifestations [Erfahrungen mit Ibuprofen 800mg retard bei ambulanten Patienten mit aktivierter Osteoarthrose und extraartikularen rheumatischen Beschwerden]. Zeitschrift für Rheumatologie 1991;50:69-76.
3. Alvart R. Multicentre trial of piroxicam in ambulant rheumatology. European Journal of Rheumatology and Inflammation 1983;6:99-105.
4. Ammitzboll F. Fenbufen and Indomethacin in the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology 1979;23:5-10.
5. Andrada SS, Rodriguez Valverde V. A double blind randomised controlled trial of droxicam versus indomehtacin in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 1991;11:15-20.
6. Appelboom T, Franchimont P. Proglumetacin versus indomethacin in rheumatoid arthritis: A double-blind multicenter study. Advances in Therapy 1994;11(5):228-34.
7. Ashcroft DM, Chapman SR, Clark WK, Millson DS. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. The Annals of Pharmacotherapy 2001;35(7-8):829-34.
8. Bernstein RM, Calin HJ, Calin A, Ollier S. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylithis. European Journal of Rheumatology and Inflammation 1992;12:6-13.
9. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine 2000;343(21):1520-8.
10. Burry HC, Sibers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. The New Zealand Medical Journal 1980;92:309-11.
11. Busson M. A long-term study of flurbiprofen in rheumatological disorders: I Rheumatoid arthritis. Journal of International Medical Research 1986;14:1-6.
12. Cardoe N, Fowler PD. Butacote: A six-year follow-up of patients with gastric intolerance to other medications. Journal of International Medical Research 1977;5(2):59-66.
13. Caruso I, Monrone F, Boari L, Davoli C, Fiorentini F. Lornoxicam versus diclofenac in rheumtoid arthritis: A double-blind multicenter study. Advances in Therapy 1994;11(3):133-8.
14. Mosca, F., Such, J. M. (2021). ELVIRA: An explainable agent for value and utility-driven multiuser privacy. In Proc. of the 20th international conference on autonomous agents and multiagent systems, AAMAS ’21, (pp. 916–924). IFAAMAS.
15. Chan FKL, Hung LCT, Suen BY, Wu JCY, Lee KC, Leung VKS, Hui AJ, To KF, W.K Leung WK, Wong VKS, Chung S, Sung JYY. Celecoxib versus diclofenac and omeprazol in reducing the risk of recurrent ulcer bleeding in patients with arthritis. The New England Journal of Medicine 2002;347(26):2104-10.
16. Chan FKL, Hung LCT, Suen BY, Wong VWS, Hui AJ, Wu JCY, Leung WK, Lee YT, To KF, Chung SCS, Sung JJY. Celecoxib versus diclofenac plus omeprazole in high risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology 2004;127:1038-43.
17. Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376(9736):173-9.
18. Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clinical Therapeutics 2000;22(4):400-10.
19. de Melo Gomes JA. The safety of arthrotec in patients with rheumatoid arthritis or osteoarthritis: An assessment of the upper gastrointestinal tract by endoscopy. Scandinavian Journal of Rheumatology 1992;96:23-31.
20. Doggrell SA. The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy 2005;6:347-50.
21. EIsen GM, Goldstein JL, Hanna DB, Rublee DA. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics 2005;21:591-8.
22. El Miedany Y, Yousef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel disease. American Journal of Gastroenterology 2006;101:311-7.
23. El-Serag HB, Sonnenber A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. The American Journal of Gastroenerology 1997;92(1):52-6.
24. Emery P, Zeidler H, Kvien TK, Geis GS. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
25. Eversmeyer W, Poland M, DeLapp RE, Jensen CP. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. The American Journal of Medicine 1993;95:10-8.
26. Fenton SF, Ryan JP, Bensen WG. A double-blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. Current Therapeutic Research 1988;66(6):1058-70.
27. Fossgreen J, Kirchheiner B, Pertersen FO, Tophoj E, Zachariae E. Clinical evaluation of ketoprofen in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;14 Suppl:93-8.
28. Franssen MJAM, Grinbnau FWJ, Van de Putte LBA. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clinical Rheumatology 1986;5(2):210-20.
29. Furst DE, Karen S, Kolba KS, Fleischmann R, Roszko PJ. Dose response and safety study of meloxicam up to 22.5mg daily in rheumatoid arthritis: A 12 week mulitcenter, double blind, dose response study versus placebo and diclofenac. The Journal of Rheumatology 2002;29(3):436-46.
30. Geis GS. Arthrotec: A therapeutic option in the management of arthritis. European Journal of Rheumatology and Inflammation 1993;13:25-32.
31. Goldstein JL, Fred E, Silverstein MD, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2-inhibitor. The American Journal of Gastroenterology 2000;95(7):1681-90.
32. Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Alimentary Pharmacology and Therapy 2004;20:527-38.
33. Graziano FM. Once-daily or twice daily administration of naproxen in patients with rheumatoid arthritis. Clinical Therapeutics 1991;13:20-5.
34. Grennan DM. Therapeutic uses of azapropazone. Scottish Medical Journal 1977;22:22-4.
35. Hernández-Diaz S, Garcia Rodriguez A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Archives of Internal Medicine 2010;160:2093-9.
36. Howard DLG. A double-blind crossover evaluation of ketoprofen and placebo in rheumatoid arthritis with assessment of long-term tolerance. The Journal of International Medical Research 1978;6:300-5.
37. Hunter JA, Parnham MJ, Balaguer I. Aceclofenac in rheumatoid arthritis: a useful and novel anti-Inflammatory. Clinical Rheumatology 1996;15(4):329-34.
38. Huskisson EC, Scott DL. A clinical comparison of two leading non-steroidal anti-inflammatory drugs. European Journal of Rheumatology and Inflammation 1991;11:4-7.
39. Huskisson EC, Ghozlan R, Kurthen R, Degners FL, Bluhmki E. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. British Journal of Rheumatology 1996;35 Suppl 1:29-34.
40. Jajic Z, Malaise M. Nekam K, Koó E, Dankó K, Kovacs M, Scarpignato C. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2005;23:809-18.
41. Karateev AE. Relapses of NSAID-induced ulcers in rheumatologic patients who continue treatment with NSAIDs (meeting abstract). Annals of Rheumatic Disease 2008;67 Suppl II:170.
42. Kean W, Buchanan W, Pelletier JP, Haraoui B, Choquette D, Senecal JL, Gascon J, Germain H, Menard H, Huang S, Elie R, Gerecz-Simon E. Open study on the efficacy and safety of long-term use of surgam-sr (sustained-release form of tiaprofenic acid) in rheumatoid arthritis patients. Inflammopharmacololgy 1993;2:63-70.
43. Kennedy AC, Germain BF, Goldman AL, Vreede PD. A double-blind crossover compariosn of ketoprofen and indomethacin in ankylosing spondylitis. Advances in Therapy 1991;8(3):148-56.
44. Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgraduate Medicine 1974;56:193-5.
45. Krueger K, Lino L, Dore R. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs. diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE II). Annals of Rheumatic Diseases 2008;67:315-22.
46. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
47. Laine L, Smith R, Min K, Chen Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapy 2006;24:751-67.
48. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Mulinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.
49. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2-selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory crug diclofenac. Gastroenterology 2008;135:1517-25.
50. Lazzaroni M, Battocchia A, Bianchi Porro G. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?. Digestive and Liver Disease 2007;39:589-96.
51. Lehtinen K. A six-month follow-up study of a slow-release indomehtacin tablet in rheumatic diseases. Clinical Rheumatology 1987;6:606-7.
52. Lisse JR. Clinical efficacy and safety of naprelan versus naprosyn in the treatment of rheumatoid arthritis. American Journal of Orthopedics 1996;25:21-9.
53. Lussier A, Camerlain M, Menard H, Myhal D, Wehner S. A double blind cross-over evaluation of ketorprofen and aspirin in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;14 Suppl:99-104.
54. Magaro M, Altomonte L, Zoli A, Mirone L, Berchicci MC, Tricerri A, Corvino G. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with non-steroidal anti-inflammatory drugs. Panminerva Medica 1989;31:16-8.
55. Manniche C, Malchow-Moller A, Andersen JR, Pedersen C, Hansen TM, Jess P, et al. Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut 1987;28(2):226-9.
56. Muller-Fassbender A. A long-term study of benorylate in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 1976;13:21-4.
57. Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Current Medical Research and Opinions 2009;25(3):729-40.
58. Nielsen OH, Ainsworht M, Csillag C, Rask-Madsen J. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or non cyclo-oxygenase inhibitors in gastroenterological high risk patients. Alimentary Pharmacology and Therapy 2006;23:27-33.
59. O'Brien W, Grunwaldt E. Ketoprofen in the treatment of rheumatoid arthritis: double blind cross-over placebo comparison. Scandinavian Journal of Rheumatology 1976;14 Suppl:105-10.
60. Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clinical Rheumatology 1996;15:473-7.
61. Porkodi R, Raghuram K, Parthiban M, Chandrasekaran AN. Therapeutic efficacy and gastric tolerance of ibuprofen at 1600-2400 mg dosage in rheumatoid arthritis. The British Journal of Clinical Practice 1987;41(12):1037-40.
62. Rahme E, Nedjar H. Risk and benefits of COX-2-inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology 2007;46:435-8.
63. Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhofer T, Lichtenberger, Vogelsang H. An open-label trial of the selective cyclo-oxygenase 2 inhibitor rofecoxib in inflammatory bowel disease associated peripheral arthritis and arthralgia. Alimentary Pharmacology and Therapy 2003;17:1371-80.
64. Richy F, Scarpignato C, Lanas A. Efficacy and safety of piroxicam revisited: a global meta-analysis of randomised control trials. Pharmacological Research 2009;60:254-63.
65. Rooney PJ, Watkins C, Ahola SJ, Gray GIL, Carson DW. A short-term double blind controlled trial of prenazone (DA2370) in rheumatoid arthritis. Current Medical Research and Opinion 1974;2:43.
66. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clinical Gastroenterology and Hepatology 2005;3:489-98.
67. Roth SH, Englund DW, Harris BK. Longterm fenoprofen therapy in patients with rheumtoid arthritis. Journal of Rheumatology 1976;2:43-8.
68. Roth SH, Bennett SE, Caldron PH, Mitchell CS, Swenson CM. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clinical Drug Investigation 1995;9(3):171-7.
69. Schmid FR, Culic DD. Anti-inflammatory drugs and gastrointestinal bleeding: a comparison of aspirin and ibuprofen. Journal of Clinical Pharmacology 1976;16:418-25.
70. Seideman P, Eriksson LO. Indomethacin in rheumatoid arthritis. Clinical Trials Journal 1988;25(5):349-58.
71. Seissiger L, Dell HD. Acetaminophen in patients with rheumatic disease with concomitant liver diseases: pharmacokinetics, effectiveness and tolerance [Acemetacin bei rheumapatienten mit leberbegleiterkrankungen pharmakokinetik, wirksamkeit und verträglichkeit]. Zeitschrift für Rheumatologie 1987;46(Suppl 1):65-9.
72. Simon B, Dammann HG, Müller P. Stomach tolerance of nonsteroidal antirheumatic drugs: comparative endoscopic study [Magenverträglichkeit nichtsteroidaler antirheumatika: endoskopische vergleichsstudien]. Zeitschrift für Rheumatologie 1987;46(Suppl.1):40-6.
73. Simpson J, Golding DN, Freeman AM, Cooke D, Hooper PA, Jamieson V, Osborne C. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. British Journal of Clinical Practice 1989;43:328-33.
74. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Archives of Internal Medicine 1996;156(14):1530-6.
75. Soni P, Shell B, Cawkwell G, Li C, Ma H. The hepatic safety and tolerability of the cyclooxgenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Current Medical Research and Opinion 2009;25(8):1841-51.
76. Tausch G, Bröll H, Dunky A, Eberl R. Comparative clinical trial with a new substance, diftalone, versus indomethacin in 30 patients with rheumatoid arthritis. Scandanavian Journal of Rheumatology 1976;5:145-50.
77. Teule M. Double-blind comparative multicenter study of the efficacy and safety of a slow release tablet of 200 mg ketoprofen once daily and a 50mg ketoprofen capsule four times daily. Current Therapeutic Research 1986;40(6):1129-46.
78. Turner R. Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1988;17(3):29-35.
79. Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib versus NSAIDs: an updated combined analysis. Current Medical Research and Opinion 2004;20(10):1539-48.
80. Wollheim FA, Lindroth Y, Sjöblom K. A comparison of ketoprofen and naproxen in rheumatoid arthritis. Rheumatology and Rehabilitation 1978;Suppl:78-83.
81. Wong WSV, Chan FKL. Cyclooxygenase-2-inhibitors in patients with high gastrointestinal risk: are we there yet?. Journal of Gastroenterololgy 2009;44 Suppl XIX:53-6.
82. Zutshi D, Mason M. Ketorprofen in rheumatoid arthritis: its tolerance and therapeutic effect. Scandinavian Journal of Rheumatology 1976;14 Suppl:77-84.
83. Akarca US. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Current Pharmaceutical Design 2005;11(14):1779-93.
84. Benson GD. Hepatotoxicity following the therapeutic use of antipyretic analgesics. American Journal of Medicine 1983;14(75):85-93.
85. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. American Journal of Therapeutics 2005;12(2):133-41.
86. Bergmann MJ. Social and economic impact of inflammatory arthritis. Postgraduate Medicine 2006;Spec No:5-11.
87. Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. Journal of Opioid Management 2010;6(4):269-89.
88. Briggs A, March L, Reid C, Lassere M, Reid C, Henderson L, et al. Baseline comorbidities in an Australian population-based cohort of rheumatoid arthritis patients receiving biological therapy: Data from the Australian Rheumatology Association Database (ARAD). International Journal of Rheumatology. 2009.
89. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology 1994;21(12):2281-5.
90. Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Alimentary Pharmacology and Therapy 2008;27(12):1224-32.
91. Khan KS, ter Riet G, Popay J, Nixon N, Kleijnen J. Study quality assessment. Undertaking Systematic Reviews of Research on Effectiveness. CRD's guidance for those carrying out or commissioning reviews. Report 4. York Publishing Services Ltd, March 2001.
92. da Silva JA, Ramiro S, Pedro S, Rodrigues A, Vasconcelos JC, Benito-Garcia E. Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatologica 2001;35(2):192-9.
93. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292(11):1363-4.
94. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester (UK): John Wiley & Sons.
95. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of Rheumatic Disease 2003;62:20-6.
96. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW. Long-term course and outcome of functional capacity in rheumatoid arthritis - The effect of disease activity and radiologic damage over time. Arthritis and Rheumatism 1999;42:1854-60.
97. Emery P. Treatment of rheumatoid arthritis. BMJ 2006;332:152-5.
98. EPOC data collection checklist. http://epoc.cochrane.org/epoc-resources-review-authors.
99. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137-45.
100. Gabriel SE. Comorbidity in arthritis. Journal of Rheumatology 1999;26:2475-9.
101. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis and Rheumatism 2002;47(4):391-7.
102. Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. International Journal of Clinical Practice 2003;135:43-9.
103. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
104. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
105. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
106. de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. British Journal of Rheumatology 1997;36(8):878-83.
107. Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD008952.pub2]
108. Michaud K. Comorbidities in rheumatoid arthritis. Best Practice & Research in Clinical Rheumatology 2007;21(5):885-906.
109. Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Practice & Research in Clinical Rheumatology 2003;17(5):729-52.
110. Minnock P, FitzGerald O, Bresnihan B. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology 2003;42(8):995-1000.
111. Moore AR, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, McQuay H. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9.
112. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Current Opinion in Gastroenterology 2010;26(6):611-7.
113. Oldroyd J, Schachna L, Buchbinder R, Staples M, Briggs A, Lassere M, Reid C, March L. Baseline characteristics in an Australian population-based cohort of patients with ankylosing spondylitis commencing biological therapy: data from the Australian Rheumatology Association Database (ARAD). International Journal of Rheumatology. 2009.
114. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346-53.
115. Prescott LF. Paracetamol, alcohol and the liver. British Journal of Clinical Pharmacology 2000;49(4):291-301.
116. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
117. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
118. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(13):1247-55.
119. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282(20):1921-8.
120. Singh G, Triadafilopoulos G. Epidemiology NSAID induced gastrointestinal complications. Journal of Rheumatology 1999;26 Suppl 56:18-24.
121. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of Rheumatic Disease 2010;69(6):964-75.
122. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
123. Ware JE, Sherbourne CD. The Mos 36-Item Short-Form Health Survey (SF-36). 1. Conceptual-Framework and Item Selection. Medical Care 1992;30:473-83.
124. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm 2009.
125. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New England Journal of Medicine 1999;340:1888-99.